William Rose - Jun 7, 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role
Director, Member of 10% owner group, 10%+ Owner
Signature
/s/ Charles E. Gale, attorney-in-fact for William E. Rose
Stock symbol
RETA
Transactions as of
Jun 7, 2023
Transactions value $
$79,943
Form type
4
Date filed
6/9/2023, 05:00 PM
Previous filing
Jun 10, 2022
Next filing
Aug 24, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RETA Stock Option (right-to-buy) Award $0 +4.28K $0.00 4.28K Jun 7, 2023 Class A common stock 4.28K $93.61 Direct F1
transaction RETA Stock Option (right-to-buy) Award $79.9K +1.09K $73.68 1.09K Jun 7, 2023 Class A common stock 1.09K $93.61 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest in four equal installments on September 7, 2023, December 7, 2023, March 7, 2024, and June 5, 2024, subject to continued service through each vesting date.
F2 These options were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $79,945.